Abstract 791P
Background
The current American Joint Committee on Cancer TNM and FIGO systems are without sufficient details encompassing the variety of ovarian cancer. To develop and validate nomograms for overall survival (OS) and cancer-specific survival (CSS) in patients with high-grade serous ovarian cancer (HGSOC).
Methods
The collection of data from California, Connecticut, Detroit, Georgia, Hawaii Iowa was formed as the development cohort. A cohort of data from Kentucky, Louisiana, New Jersey, New Mexico, Seattle, and Utah formed the external validation cohorts. We developed the nomograms using the Cox prediction model. We applied five-method comparisons to screen the best model for both nomograms, and the nomogram models underwent successful independent external validations to support their reliability. We assessed nomogram model performance by examining overall accuracy (Brier score), calibration (calibration plots and Hosmer–Lemeshow calibration test), and discrimination (Harrell C index).
Results
The development cohorts included 2465 patients which were split into two parts (7:3) for the development (n=1726) and internal validation (n=739) for the model, and the 5-year overall survival was 18·6% (458/2465). The OS nomogram showed that Scope Reg LN Sur (0-100), AJCC_N (0-89.37), Systemic Sur Seq (0-74.25), the year of diagnosis (0-69.15), and Surg Prim Site(0-51.52) shared the larger contribution to prognosis. Followed by AJCC_ M (0–48.42) and age (0–45.31). The C index of 5-year OS and CSS nomograms was 0.715 (95% CI 0.688–0.741) and 0.719 (0.693–0.745) in the development cohort, 0.695 (0.646–0.744) and 0.702 (0.653–0.750) in the internal validation cohorts. The external validation cohorts included 961 patients, were 0.684 (0.644–0.724) and 0.687 (0.648–0.727). The nomograms performed well according to overall accuracy, discrimination, and calibration when they were applied to the validation cohorts.
Conclusions
Our nomograms are credible methods that can be used to predict OS and CSS in patients with HGSOC. They should be offered to clinicians to assess patient prognosis, make prognosis-based decisions and be conducive to stratifying patients in clinical trials or population-based analyses, and inform patients clinically.
Clinical trial identification
Editorial acknowledgement
We gratefully thank the SEER database for providing data support. we also express sincere gratitude to Steve for guiding us on how to handle the data of alive or dead of other causes to perform Cause-specific survival analysis. At the same time, we thank the Free Statistics team for providing technical guidance and valuable tools for data analysis and visualization.
Legal entity responsible for the study
J. Liu.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
768P - Preliminary results of an open-label, multicentric, phase Ib/II study to assess the safety and efficacy of AsiDNA, a DNA repair inhibitor, in addition to PARP inhibitor in patients with relapsed platinum sensitive ovarian cancer already treated with PARPi for at least 6 months (RevoCAN)
Presenter: Patricia Pautier
Session: Poster session 11
769P - Pharmacokinetic boosting of olaparib: An open-label, prospective, cross-over study
Presenter: Joanneke Overbeek
Session: Poster session 11
770P - Tolerability and efficacy of trabectedin plus pegylated liposomal doxorubicin (PLD) in elderly patients with ovarian cancer (OC): GEICO 105-O study
Presenter: Maria Jesus Rubio Perez
Session: Poster session 11
771P - Genomic characterization of advanced endometrial carcinosarcoma: Identification of potentially actionable targets
Presenter: Ugo De Giorgi
Session: Poster session 11
773P - Real-world results of homologous recombination deficiency testing: Comparison between two methods on 2,655 ovarian cancer patients in Spain
Presenter: Conxi Lazaro
Session: Poster session 11
774P - CCNE1 amplification defines a good prognostic subgroup among BRCAwt/HRDneg advanced high-grade ovarian cancer (HGOC)
Presenter: Felix Blanc-Durand
Session: Poster session 11
775P - A gene expression signature to predict benefit from intraperitoneal (IP) carboplatin chemotherapy in ovarian carcinoma (OC): Translational research study from the intraperitoneal therapy for ovarian cancer with carboplatin (iPocc) phase II/III trial
Presenter: David SP Tan
Session: Poster session 11
776P - Multi-omics analysis of chemo-refractory high-grade serous carcinoma patients: Insights from the DECIDER study
Presenter: Daria Afenteva
Session: Poster session 11
777P - Targeting cadherin-6 in epithelial ovarian cancer: Clinical significance of its expression and efficacy of raludotatug deruxtecan (R-DXd) in patient-derived cell models
Presenter: Daisuke Shintani
Session: Poster session 11
778P - Combined targeting poly (ADP-ribose) polymerase and receptor tyrosine kinase inhibits ovarian clear cell carcinoma progression via disrupted ribosomal biogenesis
Presenter: Chyong-Huey Lai
Session: Poster session 11